[{"address1": "The Omeros Building", "address2": "201 Elliott Avenue West", "city": "Seattle", "state": "WA", "zip": "98119", "country": "United States", "phone": "206 676 5000", "website": "https://www.omeros.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 202, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gregory A. Demopulos M.D.", "age": 65, "title": "Co-Founder, Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1912408, "exercisedValue": 0, "unexercisedValue": 5469956}, {"maxAge": 1, "name": "Mr. David J. Borges", "age": 60, "title": "VP of Finance, Chief Accounting Officer & Treasurer", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 693676, "exercisedValue": 0, "unexercisedValue": 259606}, {"maxAge": 1, "name": "Mr. Peter B. Cancelmo J.D.", "age": 45, "title": "VP, General Counsel & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 651481, "exercisedValue": 0, "unexercisedValue": 720169}, {"maxAge": 1, "name": "Dr. Pamela Pierce Palmer M.D., Ph.D.", "age": 61, "title": "Co-Founder", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. George A. Gaitanaris M.D., Ph.D.", "age": 67, "title": "Chief Scientific Officer & VP of Science", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter W. Williams", "age": 56, "title": "Vice President of Human Resources", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Catherine A. Melfi Ph.D.", "age": 65, "title": "Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nadia  Dac", "age": 54, "title": "VP & Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Grauer M.D.", "age": 63, "title": "VP & Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David W. Ghesquiere", "age": 57, "title": "VP & Chief Business Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 6, "overallRisk": 6, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.2, "open": 4.19, "dayLow": 4.12, "dayHigh": 4.19, "regularMarketPreviousClose": 4.2, "regularMarketOpen": 4.19, "regularMarketDayLow": 4.12, "regularMarketDayHigh": 4.19, "payoutRatio": 0.0, "beta": 2.374, "forwardPE": -1.7735044, "volume": 561202, "regularMarketVolume": 561202, "averageVolume": 1117361, "averageVolume10days": 657390, "averageDailyVolume10Day": 657390, "bid": 4.1, "ask": 4.19, "bidSize": 1, "askSize": 1, "marketCap": 282431584, "fiftyTwoWeekLow": 2.95, "fiftyTwoWeekHigh": 13.6, "fiftyDayAverage": 3.9468, "twoHundredDayAverage": 6.5488, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 635698688, "profitMargins": 0.0, "floatShares": 65479913, "sharesOutstanding": 68055800, "sharesShort": 13144548, "sharesShortPriorMonth": 12783478, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.19309999, "heldPercentInsiders": 0.03785, "heldPercentInstitutions": 0.42703, "shortRatio": 11.46, "shortPercentOfFloat": 0.2007, "impliedSharesOutstanding": 68055800, "bookValue": -3.81, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -137108992, "trailingEps": -2.36, "forwardEps": -2.34, "enterpriseToEbitda": -4.628, "52WeekChange": 0.06410253, "SandP52WeekChange": 0.16885936, "quoteType": "EQUITY", "currentPrice": 4.15, "targetHighPrice": 36.0, "targetLowPrice": 9.0, "targetMeanPrice": 22.5, "targetMedianPrice": 22.5, "recommendationMean": 2.25, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 28744000, "totalCashPerShare": 0.422, "ebitda": -137363008, "totalDebt": 382011008, "quickRatio": 0.41, "currentRatio": 0.815, "returnOnAssets": -0.31063998, "grossProfits": -45443000, "freeCashflow": -70526000, "operatingCashflow": -118817000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "OMER", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Omeros Corporation", "exchange": "NGM", "messageBoardId": "finmb_32388", "market": "us_market", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "esgPopulated": false, "shortName": "Omeros Corporation", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1757716977, "regularMarketTime": 1757707201, "regularMarketChangePercent": -1.19047, "regularMarketPrice": 4.15, "priceToBook": -1.0892389, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1255008600000, "postMarketChangePercent": 0.24095787, "postMarketPrice": 4.16, "postMarketChange": 0.009999752, "regularMarketChange": -0.0499997, "regularMarketDayRange": "4.12 - 4.19", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1117361, "fiftyTwoWeekLowChange": 1.2, "fiftyTwoWeekLowChangePercent": 0.40677968, "fiftyTwoWeekRange": "2.95 - 13.6", "fiftyTwoWeekHighChange": -9.450001, "fiftyTwoWeekHighChangePercent": -0.69485295, "fiftyTwoWeekChangePercent": 6.410253, "earningsTimestamp": 1755201600, "earningsTimestampStart": 1762977600, "earningsTimestampEnd": 1762977600, "earningsCallTimestampStart": 1755203400, "earningsCallTimestampEnd": 1755203400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.36, "epsForward": -2.34, "epsCurrentYear": -2.0225, "priceEpsCurrentYear": -2.051916, "fiftyDayAverageChange": 0.2032001, "fiftyDayAverageChangePercent": 0.051484775, "twoHundredDayAverageChange": -2.3988, "twoHundredDayAverageChangePercent": -0.3662961, "displayName": "Omeros", "trailingPegRatio": null, "__fetch_time": "2025-09-13"}]